NXTC NextCure, Inc. - Common Stock
$6,92
Prix · Aoû 19, 2026
Données fondamentales au Aoû 6, 2026
Fourchette 52 semaines
$2–$16
38% of range
Note des analystes
BUY
8 analysts
Objectif de cours
$20
+189% upside
P/E (TTM)
-0.4
ROE
-172.9%
Marge nette
—
NXTC Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$6.92
Capitalisation Boursière
$25M
P/E (TTM)
-0.4
BPA (TTM)
$-19.65
Revenus (TTM)
—
Rendement div.
—
ROE
-172.9%
Dette/Capitaux propres
—
Fourchette 52 semaines
$2 – $16
NXTC Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
—
2019-12-31
→
2020-12-31
BPA
$-19.65
2020-12-31
→
2025-12-31
Flux de trésorerie libre
—
2019-12-31
→
2024-12-31
Marges
—
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
NXTC
Médiane des pairs
P/E (TTM)
-0.4
0.8
P/S (TTM)
0.9
6.2
P/B
0.7
3.0
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
NXTC
Médiane des pairs
ROA
-85.2%
-118.6%
ROE
-172.9%
-139.5%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
NXTC
Médiane des pairs
Current Ratio (Ratio de liquidité)
4.1
2.1
Quick Ratio (Ratio de liquidité réduite)
2.5
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
NXTC
Médiane des pairs
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
NXTC
Médiane des pairs
NXTC Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
8 analystes
- Achat fort 2 25,0%
- Achat 5 62,5%
- Conserver 1 12,5%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
3 analystes · 2026-08-15
Médiane
$20.00
← En dessous de tous les objectifs
$6.92
Bas
$15.00
Haut
$25.00
Objectif médian
$20.00
+188,9%
Objectif moyen
$20.00
+188,9%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
-0.74%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $-2.80 | $-1.97 | -0.83% |
| 31 mars 2026 | $-1.87 | $-2.15 | 0.28% |
| 31 décembre 2025 | $-0.81 | $-2.46 | 1.7% |
| 30 septembre 2025 | $-3.22 | $-4.06 | 0.84% |
| 30 juin 2025 | $-11.29 | $-4.71 | -6.6% |
| 31 mars 2025 | $-4.68 | $-4.90 | 0.22% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| NXTC | $50M | -0.7 | — | — | -172.9% | — |
| TVGN | — | — | — | — | — | — |
| CRVO | $73M | — | -58.9% | -673.1% | -104.4% | — |
| ELUT | — | 0.8 | -15.0% | 434.2% | -753.4% | 53.7% |
| BTAI | $36M | -0.3 | -71.7% | -10887.4% | 68.8% | — |
| QNCX | $187M | -2.0 | — | — | 700.5% | — |
| BYSI | — | — | — | — | 3.1% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | $22M | $6M | |
| R&D Expense | $45M | $41M | $48M | $54M | $50M | $47M | $34M | |
| SG&A Expense | $13M | $16M | $20M | $22M | $21M | $17M | $10M | |
| Operating Expenses | $58M | $60M | $68M | $76M | $71M | $64M | $44M | |
| Operating Income | $-58M | $-60M | $-68M | $-76M | $-71M | $-41M | $-37M | |
| Interest Expense | · | · | · | · | · | $183.0K | $209.0K | |
| Other Non-op | $2M | $4M | $5M | $1M | $1M | $5M | $4M | |
| Income Tax | $0 | · | · | · | · | · | · | |
| Net Income | $-56M | $-56M | $-63M | $-75M | $-69M | $-37M | $-34M | |
| EPS (Basic) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | · | |
| EPS (Diluted) | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 | $-1.33 | · | |
| Shares (Basic) | 2,842,448 | 2,330,386 | 27,836,584 | 27,744,209 | 27,615,977 | 27,532,177 | · | |
| Shares (Diluted) | 2,842,448 | 2,330,386 | 27,836,584 | 27,744,209 | 27,615,977 | 27,532,177 | · | |
| EBITDA | $-55M | $-57M | $-64M | $-72M | $-66M | · | $-35M |
Bilan 23
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26M | $28M | $13M | $27M | $12M | $33M | $34M | |
| Prepaid Expense | $2M | $3M | $4M | $4M | $8M | $3M | $4M | |
| Current Assets | $44M | $72M | $113M | $164M | $228M | $288M | $340M | |
| PP&E (Net) | $3M | $5M | $9M | $12M | $14M | $16M | $12M | |
| PP&E (Gross) | $29M | $29M | $29M | $29M | $27M | $24M | $17M | |
| Accum. Depreciation | $25M | $23M | $20M | $17M | $13M | $9M | $5M | |
| Other Non-current Assets | $546.0K | $332.0K | $2M | $3M | $577.0K | $3M | $4M | |
| Total Assets | $50M | $81M | $128M | $184M | $242M | $307M | $356M | |
| Accounts Payable | $2M | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | · | · | · | · | $4M | $5M | $5M | |
| Current Liabilities | $11M | $10M | $7M | $9M | $7M | $10M | $15M | |
| Capital Leases | $4M | $5M | $6M | $7M | · | · | · | |
| Other Non-current Liabilities | $526.0K | $661.0K | $785.0K | $899.0K | $2M | · | · | |
| Total Liabilities | $15M | $15M | $14M | $17M | $9M | $13M | $35M | |
| Long-term Debt | · | · | · | $0 | $0 | $4M | $5M | |
| Total Debt | · | · | · | · | · | · | $5M | |
| Common Stock | $4.0K | $2.0K | $28.0K | $28.0K | $28.0K | $28.0K | $27.0K | |
| Paid-in Capital | $471M | $446M | $439M | $431M | $421M | $411M | $403M | |
| Retained Earnings | $-436M | $-380M | $-324M | $-262M | $-187M | $-118M | $-81M | |
| AOCI | $21.0K | $4.0K | $-222.0K | $-1M | $-663.0K | $779.0K | $-38.0K | |
| Stockholders' Equity | $35M | $65M | $114M | $168M | $233M | $294M | $321M | |
| Liabilities + Equity | $50M | $81M | $128M | $184M | $242M | $307M | $356M | |
| Shares Outstanding | 3,505,621 | 2,333,896 | 2,325,259 | 27,774,536 | 27,680,997 | 27,568,802 | 27,499,260 |
Flux de trésorerie 11
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $3M | $4M | $4M | $4M | $3M | $3M | |
| Stock-based Comp | $3M | $6M | $8M | $10M | $10M | $8M | $2M | |
| Other Non-cash | $1M | $6M | $-2M | $7M | $-2M | · | $-6M | |
| Operating Cash Flow | $-50M | $-41M | $-53M | $-54M | $-57M | $-45M | $-36M | |
| CapEx | · | $474.0K | $820.0K | $2M | $2M | $7M | $3M | |
| Investing Cash Flow | $26M | $55M | $39M | $68M | $37M | $44M | $-304M | |
| Stock Issued | · | $39.0K | $5.0K | · | · | $112.0K | $119.0K | |
| Net Stock Activity | · | $39.0K | · | · | · | · | $119.0K | |
| Financing Cash Flow | $22M | $144.0K | $154.0K | $200.0K | $-3M | $-1M | $243M | |
| Net Change in Cash | $-2M | $15M | $-14M | $14M | $-24M | $-3M | $-97M | |
| Free Cash Flow | · | $-41M | $-54M | $-56M | $-60M | · | $-39M |
Rentabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | -590.5% | |
| Net Margin | · | · | · | · | · | · | -531.5% | |
| EBITDA Margin | · | · | · | · | · | · | -548.0% | |
| ROA | -85.2% | -53.3% | -40.2% | -35.0% | -25.3% | · | -13.4% | |
| ROE | -172.9% | -78.9% | -52.1% | -42.8% | -28.8% | · | -13.7% |
Liquidité et Solvabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 7.5 | 16.4 | 18.0 | 34.5 | · | 22.6 | |
| Quick Ratio | 2.5 | 2.9 | 1.9 | 2.9 | 1.9 | · | 2.3 | |
| Debt / Equity | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | -179.3 |
Efficacité 1
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | 0.0 |
Valorisation (TTM) 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $27M | $27M | $27M | $27M | $22M | $6M | |
| Net Income TTM | $-56M | $-56M | $-63M | $-75M | $-69M | $-37M | $-34M | |
| Market Cap | $50M | $259M | $382M | $470M | $1.99B | · | $18.59B | |
| Enterprise Value | · | · | · | · | · | · | $18.56B | |
| P/E | -0.7 | -0.4 | -6.1 | -6.3 | -28.7 | -98.3 | · | |
| P/S | 1.9 | 9.7 | 14.3 | 17.6 | 74.6 | · | 2928.7 | |
| P/B | 1.4 | 4.0 | 3.3 | 2.8 | 8.5 | · | 57.8 | |
| P / Tangible Book | 1.4 | 4.0 | 3.3 | 2.8 | 8.5 | 12.3 | · | |
| P / Cash Flow | -1.0 | -6.4 | -7.2 | -8.7 | -34.8 | · | -521.8 | |
| P / FCF | · | -6.3 | -7.1 | -8.4 | -33.4 | · | -476.7 | |
| EV / EBITDA | · | · | · | · | · | · | -533.6 | |
| EV / FCF | · | · | · | · | · | · | -476.0 | |
| EV / Revenue | · | · | · | · | · | · | 2924.1 | |
| Earnings Yield | -138.5% | -258.1% | -16.4% | -15.9% | -3.5% | -1.0% | · |
Compte de résultat 12
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $7M | $7M | $7M | $6M | $24M | $8M | $9M | $9M | $12M | $11M | $12M | $11M | $13M | $12M | $13M | $14M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $6M | $5M | $5M | $6M | |
| Operating Expenses | $15M | $10M | $10M | $9M | $27M | $12M | $12M | $12M | $16M | $18M | $16M | $16M | $19M | $17M | $18M | $19M | |
| Operating Income | $-15M | $-10M | $-10M | $-9M | $-27M | $-12M | $-12M | $-12M | $-16M | $-18M | $-16M | $-16M | $-19M | $-17M | $-18M | $-19M | |
| Other Non-op | $202.0K | $309.0K | $321.0K | $321.0K | $484.0K | $646.0K | $852.0K | $955.0K | $1M | $1M | $1M | $1M | $1M | $975.0K | $471.0K | $328.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Net Income | $-15M | $-10M | $-9M | $-9M | $-27M | $-11M | $-12M | $-12M | $-15M | $-17M | $-14M | $-14M | $-18M | $-16M | $-17M | $-19M | |
| EPS (Basic) | $-2.80 | $-1.87 | $-4.75 | $-3.22 | $-11.29 | $-4.70 | $-11.71 | $-4.95 | $-6.61 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.58 | $-0.62 | $-0.68 | |
| EPS (Diluted) | $-2.80 | $-1.87 | $-4.75 | $-3.22 | $-11.29 | $-4.70 | $-11.71 | $-4.95 | $-6.61 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.58 | $-0.62 | $-0.68 | |
| Shares (Basic) | 5,309,724 | 5,239,236 | -30,215,081 | 2,676,116 | 2,374,729 | 2,333,890 | -30,235,036 | 2,331,320 | 2,331,062 | 27,903,040 | -55,606,661 | 27,839,968 | 27,828,741 | 27,774,536 | -55,458,165 | 27,748,844 | |
| Shares (Diluted) | 5,309,724 | 5,239,236 | -30,215,081 | 2,676,116 | 2,374,729 | 2,333,890 | -30,235,036 | 2,331,320 | 2,331,062 | 27,903,040 | -55,606,661 | 27,839,968 | 27,828,741 | 27,774,536 | -55,458,165 | 27,748,844 | |
| EBITDA | $-15M | $-10M | · | $-9M | $-27M | $-12M | · | $-12M | $-16M | $-18M | · | $-16M | $-19M | $-17M | · | $-19M |
Bilan 21
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $15M | $26M | $7M | $5M | $22M | $28M | $28M | $21M | $18M | $13M | $20M | $22M | $30M | $27M | $31M | |
| Prepaid Expense | $2M | $2M | $2M | $4M | $5M | $3M | $3M | $3M | $4M | $7M | $4M | $4M | $5M | $3M | $4M | $6M | |
| Current Assets | $22M | $32M | $44M | $33M | $40M | $59M | $72M | $79M | $90M | $103M | $113M | $123M | $135M | $149M | $164M | $175M | |
| PP&E (Net) | $283.0K | $3M | $3M | $4M | $4M | $5M | $5M | $6M | $7M | $7M | $9M | $10M | $11M | $11M | $12M | $12M | |
| PP&E (Gross) | · | · | $29M | · | · | · | $29M | · | · | · | $29M | · | · | · | $29M | · | |
| Accum. Depreciation | · | · | $25M | · | · | · | $23M | · | · | · | $20M | · | · | · | $17M | · | |
| Other Non-current Assets | $82.0K | $847.0K | $546.0K | $550.0K | $555.0K | $328.0K | $332.0K | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | |
| Total Assets | $23M | $38M | $50M | $40M | $48M | $67M | $81M | $90M | $103M | $115M | $128M | $140M | $153M | $168M | $184M | $190M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $3M | $3M | $5M | $4M | $5M | $4M | $2M | $3M | $3M | $2M | $4M | $2M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Current Liabilities | $6M | $7M | $11M | $11M | $11M | $6M | $10M | $9M | $11M | $10M | $7M | $7M | $8M | $6M | $9M | $6M | |
| Capital Leases | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $7M | · | |
| Other Non-current Liabilities | $455.0K | $491.0K | $526.0K | $561.0K | $596.0K | $629.0K | $661.0K | $693.0K | $725.0K | $755.0K | $785.0K | $815.0K | $843.0K | $872.0K | $899.0K | · | |
| Total Liabilities | $10M | $11M | $15M | $16M | $16M | $11M | $15M | $15M | $17M | $16M | $14M | $13M | $15M | $14M | $17M | $8M | |
| Common Stock | $4.0K | $4.0K | $4.0K | $3.0K | $2.0K | $28.0K | $2.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | |
| Paid-in Capital | $473M | $472M | $471M | $450M | $448M | $447M | $446M | $444M | $442M | $441M | $439M | $437M | $435M | $433M | $431M | $428M | |
| Retained Earnings | $-461M | $-446M | $-436M | $-427M | $-418M | $-391M | $-380M | $-369M | $-357M | $-342M | $-324M | $-310M | $-296M | $-278M | $-262M | $-244M | |
| AOCI | $-3.0K | $-2.0K | $21.0K | $17.0K | $-7.0K | · | $4.0K | $76.0K | $-86.0K | $-182.0K | $-222.0K | $-603.0K | $-925.0K | $-803.0K | $-1M | $-2M | |
| Stockholders' Equity | $12M | $27M | $35M | $24M | $30M | $56M | $65M | $76M | $85M | $99M | $114M | $126M | $138M | $154M | $168M | $182M | |
| Liabilities + Equity | $23M | $38M | $50M | $40M | $48M | $67M | $81M | $90M | $103M | $115M | $128M | $140M | $153M | $168M | $184M | $190M | |
| Shares Outstanding | 4,068,951 | 3,607,555 | 3,505,621 | 2,676,110 | 2,337,516 | 28,006,684 | 2,333,896 | 27,975,840 | 27,975,840 | 27,903,627 | 27,903,027 | 27,839,968 | 27,839,968 | 27,774,536 | 27,774,536 | 27,748,844 |
Flux de trésorerie 9
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $304.0K | $344.0K | $435.0K | $600.0K | $588.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-10M | $-13M | $-8M | $-6M | $-23M | $-13M | $-7M | $-11M | $-10M | $-13M | $-11M | $-13M | $-15M | $-15M | $-9M | $-15M | |
| CapEx | · | · | · | · | · | · | $-34.0K | $170.0K | $301.0K | $37.0K | $13.0K | $279.0K | $280.0K | $248.0K | $865.0K | $532.0K | |
| Investing Cash Flow | $10M | $1M | $6M | $9M | $4M | $7M | $7M | $18M | $12M | $18M | $4M | $10M | $7M | $18M | $4M | $18M | |
| Stock Issued | $0 | $1M | · | · | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $1M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $22.0K | $1M | $20M | $0 | · | · | $37.0K | $0 | $106.0K | $1.0K | $71.0K | $0 | · | · | $61.0K | $0 | |
| Net Change in Cash | $93.0K | $-11M | $19M | $2M | $-17M | $-6M | $26.0K | $7M | $2M | $5M | $-6M | $-2M | $-8M | $3M | $-4M | $3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-13M | · | · | · | $-15M | · | · |
Rentabilité 2
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -42.4% | -18.6% | · | -13.3% | -35.7% | -12.0% | · | -10.0% | -12.0% | -12.1% | · | -8.7% | -9.9% | -8.2% | · | -8.5% | |
| ROE | -71.3% | -23.7% | · | -17.4% | -46.6% | -14.2% | · | -11.4% | -13.8% | -13.5% | · | -9.3% | -10.6% | -8.7% | · | -8.8% |
Liquidité et Solvabilité 2
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.6 | · | 3.0 | 3.7 | 10.3 | · | 9.1 | 8.3 | 10.7 | · | 18.7 | 17.3 | 23.8 | · | 29.8 | |
| Quick Ratio | 2.4 | 2.2 | · | 0.7 | 0.5 | 3.8 | · | 3.2 | 1.9 | 1.9 | · | 3.0 | 2.8 | 4.8 | · | 5.3 |
Valorisation (TTM) 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $27M | · | $27M | $27M | $27M | · | $27M | $27M | $27M | · | $27M | $27M | $27M | · | $27M | |
| Net Income TTM | $-60M | $-56M | · | $-58M | $-65M | $-55M | · | $-58M | $-65M | $-65M | · | $-67M | $-71M | $-74M | · | $-75M | |
| Market Cap | $7M | $39M | · | $16M | $13M | $161M | · | $460M | $534M | $747M | · | $431M | $601M | $493M | · | $916M | |
| P/E | -0.1 | -0.5 | · | -0.3 | -0.2 | -0.5 | · | -1.3 | -2.3 | -11.4 | · | -6.4 | -8.5 | -6.7 | · | -12.1 | |
| P/S | 0.2 | 1.4 | · | 0.6 | 0.5 | 6.0 | · | 17.2 | 20.0 | 27.9 | · | 16.1 | 22.5 | 18.5 | · | 34.3 | |
| P/B | 0.5 | 1.4 | · | 0.7 | 0.4 | 2.9 | · | 6.1 | 6.2 | 7.5 | · | 3.4 | 4.3 | 3.2 | · | 5.0 | |
| P / Tangible Book | 0.5 | 1.4 | · | 0.7 | 0.4 | 2.9 | · | 6.1 | 6.2 | 7.5 | · | 3.4 | 4.3 | 3.2 | · | 5.0 | |
| P / Cash Flow | · | -2.9 | · | · | · | -12.4 | · | · | · | -59.2 | · | · | · | -33.4 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -59.1 | · | · | · | -32.8 | · | · | |
| Earnings Yield | -1198.8% | -197.4% | · | -338.7% | -421.0% | -218.1% | · | -77.1% | -43.9% | -8.7% | · | -15.6% | -11.8% | -14.9% | · | -8.2% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Résultat net | $-56M | $-56M | $-63M | $-75M | $-69M |
| BPA dilué | $-19.65 | $-23.88 | $-2.25 | $-2.69 | $-2.51 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 4.1 | 7.5 | 16.4 | 18.0 | 34.5 |
| Ratio de liquidité réduite | 2.5 | 2.9 | 1.9 | 2.9 | 1.9 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | — | $-41M | $-54M | $-56M | $-60M |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 31 déclarants · $2.7M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 11 (+4 vs T. préc.) | 7 (+3 vs T. préc.) | 5 (+2 vs T. préc.) | 7 (+3 vs T. préc.) | -363K |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| Ikarian Capital, LLC | $461 284 | 288 303 | 17,31% | Actions |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $443 523 | 277 202 | 16,65% | Actions |
| Sofinnova Investments, Inc. | $356 246 | 222 654 | 13,37% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $273 923 | 171 202 | 10,28% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $250 947 | 156 842 | 9,42% | Actions |
| MILLENNIUM MANAGEMENT LLC | $140 979 | 88 112 | 5,29% | Actions |
| VANGUARD GROUP INC | $136 692 | 9 633 | 5,13% | Actions |
| BOOTHBAY FUND MANAGEMENT, LLC | $135 499 | 84 687 | 5,09% | Actions |
| Squadron Capital Management LLC | $103 142 | 64 464 | 3,87% | Actions |
| Verdad Advisers, LP | $96 722 | 60 451 | 3,63% | Actions |
| Affinity Asset Advisors, LLC | $67 136 | 41 960 | 2,52% | Actions |
| JANE STREET GROUP, LLC | $39 198 | 24 499 | 1,47% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $38 236 | 23 893 | 1,44% | Actions |
| CARDIFF PARK ADVISORS, LLC | $34 933 | 21 833 | 1,31% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $25 814 | 16 134 | 0,97% | Actions |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $20 000 | 12 500 | 0,75% | Actions |
| DIADEMA PARTNERS LP | $12 387 | 7 742 | 0,46% | Actions |
| Pfizer Inc | $11 533 | 7 001 | 0,43% | Actions |
| BARCLAYS PLC | $9 002 | 5 626 | 0,34% | Actions |
| Persistent Asset Partners Ltd | $3 170 | 1 981 | 0,12% | Actions |
| Tower Research Capital LLC (TRC) | $2 781 | 1 738 | 0,10% | Actions |
| UBS Group AG | $501 | 313 | 0,02% | Actions |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $133 | 83 | 0,00% | Actions |
| BlackRock, Inc. | $117 | 73 | 0,00% | Actions |
| JPMORGAN CHASE & CO | $107 | 61 | 0,00% | Actions |
| MORGAN STANLEY | $106 | 66 | 0,00% | Actions |
| HRT FINANCIAL LP | $58 | 36 450 | 0,00% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $51 | 32 | 0,00% | Actions |
| SBI Securities Co., Ltd. | $32 | 20 | 0,00% | Actions |
| ACADIAN ASSET MANAGEMENT LLC | $30 | 18 982 | 0,00% | Actions |
| Virtu Financial LLC | $18 | 10 991 | 0,00% | Actions |
Initiés de la société 23 initiés · 11 dirigeants · 13 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Richman | President & CEO | 30 janvier 2026 A | — | 0 | 0 | $0 |
| Steven P. Cobourn | Chief Financial Officer | 30 janvier 2026 A | — | 0 | 0 | $0 |
| Timothy Mayer | Chief Operating Officer | 30 janvier 2026 A | — | 0 | 0 | $0 |
| Udayan Guha | Chief Medical Officer | 30 janvier 2026 A | — | 0 | 0 | $0 |
| Kevin G. Shaw | Sr VP, General Counsel | 30 janvier 2026 A | — | 0 | 0 | $0 |
| Sourav Kundu | Sr VP, Dev. & Mfg. | 30 janvier 2026 A | — | 0 | 0 | $0 |
| Sol Langermann | Chief Scientific Officer | 31 janvier 2025 A | — | 0 | 0 | $0 |
| Han Myint | Chief Medical Officer | 29 mars 2024 A | — | 0 | 0 | $0 |
| Linda Liu | SVP, Research | 31 janvier 2022 A | 55 234 | 0 | 0 | $0 |
| Kevin N. Heller | Chief Medical Officer | 14 juillet 2020 M | 49 011 | 0 | 0 | $0 |
| James B. Bingham | Chief Development Officer | 28 février 2020 A | — | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Administrateur | 18 juin 2026 A | — | 0 | 0 | $0 |
| Ellen Feigal | Administrateur | 18 juin 2026 A | — | 0 | 0 | $0 |
| John G Houston | Administrateur | 18 juin 2026 A | — | 0 | 0 | $0 |
| Stephen W Webster | Administrateur | 18 juin 2026 A | — | 0 | 0 | $0 |
| Elaine V Jones | Administrateur | 18 juin 2026 A | — | 0 | 0 | $0 |
| KABAKOFF DAVID S | Administrateur | 18 juin 2026 A | — | 0 | 0 | $0 |
| Garry A Nicholson | Administrateur | 22 juin 2023 A | — | 0 | 0 | $0 |
| Chau Quang Khuong | Administrateur | 22 juin 2023 A | 2 711 013 | 0 | 0 | $0 |
| Judith Li | Administrateur | 11 juin 2020 A | — | 0 | 0 | $0 |
| Stella Xu | Administrateur | 11 juin 2020 A | 1 103 570 | 0 | 0 | $0 |
| Briggs Morrison | Administrateur | 11 juin 2020 A | — | 0 | 0 | $0 |
| Timothy M Shannon | Administrateur | 13 juin 2019 A | 2 254 442 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 3 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Sofinnova Venture Partners IX, L.P. ("SVP IX"), Sofinnova Management IX, L.L.C. ("SM IX"), Dr. James I. Healy ("Healy") | 5 mars 2026 | 7,10% | Amendement | Investissement passif | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC ×3 dépôts | 8 mars 2024 | — | Dépôt initial | — | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×2 dépôts | 22 novembre 2019 | — | Dépôt initial | Investissement passif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 5 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0,00% | 9 851 SH | 8 août 2026 | Quotidien |
| DCOR · Dimensional ETF Trust | 0,00% | 822 NS | 30 avril 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 2 392 NS | 30 avril 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 33 566 SH | 8 août 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 123 276 SH | 8 août 2026 | Quotidien |